New data with Takeda’s TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS’s Sotyktu in the treatment of psoriasis.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844